S

Sandoz Group AG
SIX:SDZ

Watchlist Manager
Sandoz Group AG
SIX:SDZ
Watchlist
Price: 37.06 CHF -0.22% Market Closed
Market Cap: 16.3B CHF
Have any thoughts about
Sandoz Group AG?
Write Note

Sandoz Group AG
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sandoz Group AG
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
S
Sandoz Group AG
SIX:SDZ
Net Income (Common)
$77m
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Novartis AG
SIX:NOVN
Net Income (Common)
$17.6B
CAGR 3-Years
22%
CAGR 5-Years
8%
CAGR 10-Years
5%
Roche Holding AG
SIX:ROG
Net Income (Common)
CHf11.5B
CAGR 3-Years
-7%
CAGR 5-Years
2%
CAGR 10-Years
0%
No Stocks Found

Sandoz Group AG
Glance View

Market Cap
15.9B CHF
Industry
Pharmaceuticals

Sandoz Group AG, a renowned player in the pharmaceutical industry, stands as a global leader in the production of generic drugs and biosimilars. Originally part of the Swiss corporate giant Novartis, Sandoz has cultivated a reputation for delivering affordable healthcare solutions across the globe. Its foundation lies in the manufacturing of cost-effective, high-quality alternatives to branded medicines, making healthcare more accessible to a broader public. By focusing on generic pharmaceuticals—drugs that are comparable to branded products in terms of dosage, safety, strength, quality, and performance—Sandoz effectively manages to carve out a vital niche in the healthcare ecosystem. This strategic emphasis allows the company to offer a vast portfolio that spans across major therapeutic areas such as cardiovascular, central nervous system, pain management, and oncology, to name a few. Sandoz's business model hinges on its ability to streamline production processes and efficiently navigate regulatory landscapes, which enables the company to sell its products at competitive prices while maintaining profitability. One critical aspect of their operation is the capability to innovate within the generic space, exemplified by their expansion into biosimilars—biopharmaceutical drugs that are highly akin to existing biological products. As patents for major biologics expire, Sandoz capitalizes on the opportunity to introduce biosimilars, thus broadening access to complex therapies. The company invests significantly in research and development to enhance its pipeline of generic drugs and biosimilars, ensuring a steady flow of new market entries. Through a combination of strategic pricing, diverse product offerings, and robust R&D efforts, Sandoz sustains its business model while contributing profoundly to global health, embodying a mission of "Pioneering Access for Patients."

SDZ Intrinsic Value
45.22 CHF
Undervaluation 18%
Intrinsic Value
Price
S

See Also

What is Sandoz Group AG's Net Income (Common)?
Net Income (Common)
77m USD

Based on the financial report for Dec 31, 2023, Sandoz Group AG's Net Income (Common) amounts to 77m USD.

What is Sandoz Group AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-45%

Over the last year, the Net Income (Common) growth was -91%. The average annual Net Income (Common) growth rates for Sandoz Group AG have been -45% over the past three years .

Back to Top